A few decades ago, nobody really questioned vaccines. They were viewed as a standard part of staying healthy and safe. Today, the number of people questioning vaccines risks prolonging a pandemic that has already killed hundreds of thousands of Americans. How we got to this moment didn’t start with the rollout of vaccines or in March 2020, or even with the election of Donald Trump. Our confidence in vaccines, often isn't even about vaccines. It’s about trust. And that trust has been eroding for a long time. Doubt, a new series from Bloomberg’s Prognosis podcast, looks at the forces that have been breaking down that trust. We'll trace the rise of vaccine skepticism in America to show how we got here — and where we’re going. Doubt launches on March 23. Subscribe to Prognosis today on Apple Podcasts, Spotify or wherever you get your podcasts.
See omnystudio.com/listener for privacy information.
61: Oh The Humana-ty
60: J&J Nears Actelion Takeover Despite Twists and Turns
59: Mars Matches M&Ms with Animal Hospitals
58: 2nd Annual Brooke Sutherland M&A Predictions Extravaganza
57: 2016 M&A Year in Review
56: Fox Agrees to Buy Sky While CBS and Viacom Stay Split
55: What Does Donald Trump Mean for 2017 M&A?
54: The Future of Media M&A After Trump's Victory
53: FanDuel and DraftKings Finally Agree to Merge
52: Twinkies Rise Again
51: Forget The Election, M&A is Rigged, NYU Professor Says
50: CenturyLink Buys Level 3; Gannett Gets Tronced
49: How We Broke AT&T's Discussions to Buy Time Warner
48: Snapchat's Lessons from Twitter and Facebook
47: Qualcomm Hunts Car Computer Chips in Biggest 2016 Tech Deal
46: Redo! Putting CBS and Viacom Back Together
45: CBOE's $3 Billion Bats Purchase Is Actually a Tech Deal
44: Rob and Andy Kindler Telling Jokes
43: Where Oh Where Did All the IPOs Go?
42: Just Hoping Twitter Is for Sale Doesn't Make it True
Create your
podcast in
minutes
It is Free
The Commercial Edge: Unleash the Power of People
The emPOWERed Half Hour
Masters in Business
Odd Lots
Bloomberg Surveillance
Bloomberg Businessweek
Prognosis: Losing it